海南海药涨2.12%，成交额5.97亿元，主力资金净流出4237.63万元

Core Viewpoint - Hainan Haiyao's stock price has shown significant volatility, with a year-to-date increase of 51.15%, but a recent decline of 12.56% over the past five trading days [1] Group 1: Stock Performance - As of December 31, Hainan Haiyao's stock price was 7.24 CNY per share, with a trading volume of 5.97 billion CNY and a turnover rate of 6.45%, resulting in a total market capitalization of 93.93 billion CNY [1] - The stock has experienced a 12.56% decline over the last five trading days and a 10.95% decline over the last 20 days, while it has increased by 31.64% over the last 60 days [1] - The company has appeared on the trading leaderboard 10 times this year, with the most recent appearance on December 23, where it recorded a net buy of 241 million CNY [1] Group 2: Company Overview - Hainan Haiyao, established on December 30, 1992, and listed on May 25, 1994, is located in Haikou, Hainan Province, and its main business includes traditional and Western medicine, fine chemicals, chemical raw materials, health products, and related import-export trade [2] - The company's revenue composition includes: Other varieties 29.93%, Gastrointestinal health 25.07%, Medical services 18.60%, Raw materials and intermediates 13.27%, Cephalosporin series 10.19%, and Others 2.95% [2] - Hainan Haiyao is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations, with concepts including anticancer drugs, innovative drugs, antiviral drugs, traditional Chinese medicine, and raw materials [2] Group 3: Financial Performance - For the period from January to September 2025, Hainan Haiyao reported revenue of 640 million CNY, a year-on-year decrease of 20.51%, and a net profit attributable to shareholders of -242 million CNY, reflecting a year-on-year increase of 17.91% [2] - The company has distributed a total of 466 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which held 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]